Literature DB >> 27392607

Epigenetic regulation of epithelial-mesenchymal transition.

Lidong Sun1, Jia Fang2.   

Abstract

Epithelial-mesenchymal transition (EMT) is an essential process for morphogenesis and organ development which reversibly enables polarized epithelial cells to lose their epithelial characteristics and to acquire mesenchymal properties. It is now evident that the aberrant activation of EMT is also a critical mechanism to endow epithelial cancer cells with migratory and invasive capabilities associated with metastatic competence. This dedifferentiation program is mediated by a small cohort of pleiotropic transcription factors which orchestrate a complex array of epigenetic mechanisms for the wide-spread changes in gene expression. Here, we review major epigenetic mechanisms with an emphasis on histone modifications and discuss their implications in EMT and tumor progression. We also highlight mechanisms underlying transcription regulation concerted by various chromatin-modifying proteins and EMT-inducing transcription factors at different molecular layers. Owing to the reversible nature of epigenetic modifications, a thorough understanding of their functions in EMT will not only provide new insights into our knowledge of cancer progression and metastasis, but also facilitate the development of diagnostic and therapeutic strategies for human malignancy.

Entities:  

Keywords:  Epigenetics; Epithelial–mesenchymal transition; Histone modifications; Transcription regulation; Tumor progression

Mesh:

Substances:

Year:  2016        PMID: 27392607      PMCID: PMC5459373          DOI: 10.1007/s00018-016-2303-1

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  251 in total

1.  Chromosomal instability and tumors promoted by DNA hypomethylation.

Authors:  Amir Eden; François Gaudet; Alpana Waghmare; Rudolf Jaenisch
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

2.  Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells.

Authors:  Yohei Shimono; Maider Zabala; Robert W Cho; Neethan Lobo; Piero Dalerba; Dalong Qian; Maximilian Diehn; Huiping Liu; Sarita P Panula; Eric Chiao; Frederick M Dirbas; George Somlo; Renee A Reijo Pera; Kaiqin Lao; Michael F Clarke
Journal:  Cell       Date:  2009-08-07       Impact factor: 41.582

Review 3.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

4.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

Authors:  Steven D Gore; Stephen Baylin; Elizabeth Sugar; Hetty Carraway; Carole B Miller; Michael Carducci; Michael Grever; Oliver Galm; Tianna Dauses; Judith E Karp; Michelle A Rudek; Ming Zhao; B Douglas Smith; Jasper Manning; Anchalee Jiemjit; George Dover; Abbie Mays; James Zwiebel; Anthony Murgo; Li-Jun Weng; James G Herman
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

5.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

6.  Histone recognition by human malignant brain tumor domains.

Authors:  Nataliya Nady; Liubov Krichevsky; Nan Zhong; Shili Duan; Wolfram Tempel; Maria F Amaya; Mani Ravichandran; Cheryl H Arrowsmith
Journal:  J Mol Biol       Date:  2012-09-04       Impact factor: 5.469

7.  Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer.

Authors:  Tangfeng Lv; Dongmei Yuan; Xiaohui Miao; Yanling Lv; Ping Zhan; Xiaokun Shen; Yong Song
Journal:  PLoS One       Date:  2012-04-06       Impact factor: 3.240

8.  LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis.

Authors:  P Hou; Y Zhao; Z Li; R Yao; M Ma; Y Gao; L Zhao; Y Zhang; B Huang; J Lu
Journal:  Cell Death Dis       Date:  2014-06-12       Impact factor: 8.469

9.  Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.

Authors:  P Dong; M Karaayvaz; N Jia; M Kaneuchi; J Hamada; H Watari; S Sudo; J Ju; N Sakuragi
Journal:  Oncogene       Date:  2012-07-30       Impact factor: 9.867

10.  Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.

Authors:  Molly Gale; Joyce Sayegh; Jian Cao; Michael Norcia; Peter Gareiss; Denton Hoyer; Jane S Merkel; Qin Yan
Journal:  Oncotarget       Date:  2016-06-28
View more
  41 in total

1.  Assembly of human C-terminal binding protein (CtBP) into tetramers.

Authors:  Andrew G Bellesis; Anne M Jecrois; Janelle A Hayes; Celia A Schiffer; William E Royer
Journal:  J Biol Chem       Date:  2018-04-26       Impact factor: 5.157

2.  2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol reverses EGF-induced cell migration and invasion through down-regulation of MDM2 in breast cancer cell lines.

Authors:  Dayong Zheng; Xing Chang; Yang Liu; Jingwen Xu; Wenfeng Gou; Zengqiang Li; Daiying Zuo; Weige Zhang; Yingliang Wu
Journal:  Cancer Biol Ther       Date:  2018-12-04       Impact factor: 4.742

Review 3.  Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?

Authors:  Jente van Staalduinen; David Baker; Peter Ten Dijke; Hans van Dam
Journal:  Oncogene       Date:  2018-07-12       Impact factor: 9.867

4.  MEG8 long noncoding RNA contributes to epigenetic progression of the epithelial-mesenchymal transition of lung and pancreatic cancer cells.

Authors:  Minoru Terashima; Akihiko Ishimura; Sasithorn Wanna-Udom; Takeshi Suzuki
Journal:  J Biol Chem       Date:  2018-09-27       Impact factor: 5.157

5.  STEAP2 is down-regulated in breast cancer tissue and suppresses PI3K/AKT signaling and breast cancer cell invasion in vitro and in vivo.

Authors:  Qing Yang; Guoxin Ji; Jiyu Li
Journal:  Cancer Biol Ther       Date:  2019-11-07       Impact factor: 4.742

6.  Silencing of kallikrein-related peptidase 6 attenuates the proliferation, migration, and invasion of gastric cancer cells through inhibition of epithelial-mesenchymal transition.

Authors:  Dong Zhou; Yanping He; Hengping Li; Weidong Huang
Journal:  Exp Ther Med       Date:  2021-05-17       Impact factor: 2.447

Review 7.  Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

Authors:  Laura Amicone; Alessandra Marchetti
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-02

Review 8.  Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression.

Authors:  Nirmalya Saha; Andrew G Muntean
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-26       Impact factor: 10.680

9.  Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial-mesenchymal transition.

Authors:  Lirong Liu; Jianan Zou; Yingjie Guan; Yunhe Zhang; Wei Zhang; Xiaoxu Zhou; Chongxiang Xiong; Evelyn Tolbert; Ting C Zhao; George Bayliss; Shougang Zhuang
Journal:  FASEB J       Date:  2019-08-02       Impact factor: 5.191

10.  Aberrant JmjC domain-containing protein 8 (JMJD8) expression promotes activation of AKT and tumor epithelial-mesenchymal transition.

Authors:  Yao Su; Xueying Wang; Zhen Guo; Jun Wang
Journal:  Oncogene       Date:  2020-09-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.